Table 3.
ORRs per investigator and independent assessment
| Response, n (%) | Investigator assessment | Independent assessment | ||
|---|---|---|---|---|
| ITT Assessable (n = 36) | BRAF V600E Assessablea (n = 33) | ITT Assessable (n = 36) | BRAF V600E Assessablea (n = 33) | |
| ORR | 20 (56) | 20 (61) | 19 (53) | 19 (58) |
| 95% CI | 38.1–72.1 | 42.1–77.1 | 35.5–69.6 | 39.2–74.5 |
| CR | 3 (8) | 3 (9) | 2 (6) | 2 (6) |
| PR | 17 (47) | 17 (52) | 17 (47) | 17 (52) |
| SD | 11 (31) | 8 (24) | 8 (22) | 6 (18) |
| PD | 4 (11) | 4 (12) | 8 (22) | 7 (21) |
| NA | 1 (3) | 1 (3) | 1 (3) | 1 (3) |
CI, confidence interval; CR, complete response; ITT, intent-to-treat; NA, not assessable; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.
a
Includes patients with centrally confirmed BRAF V600E-mutant disease.